Beam Therapeutics Analyst Price Targets

Beam Therapeutics Inc

BEAMNASDAQ

Trade with Public

$24.19

0.723.07%

Dern. MÀJ: Oct 19, 4:26 PM

$24.19

0.723.07%

Aperçu Actualités Prévisions de résultats ÉvénementsObjectifs de coursDonnées financières Sentiment Actionnariat Comparer Options Rapport sur les stocks

Beam Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Beam Therapeutics (BEAM).

Price Target Range — 13 Quarters

Analyst Consensus — 18 Analysts

15Buy

3Hold

Consensus RatingBuy# Analysts18Avg. Consensus PT$49Upside to Avg. PT+104.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 15, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$80
Oct 14, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$65
Sep 9, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$65
Aug 25, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$80
Jul 8, 2026	B of A Securities	Alec Stranahan	Maintained	Buy	$47
Jul 7, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$80
May 13, 2026	Bernstein	William Pickering	PT Cut	Outperform	$40→$39
Mar 26, 2026	Citigroup	Samantha Semenkow	PT Raise	Buy	$64→$68
Feb 25, 2026	RBC Capital	Luca Issi	PT Raise	Sector Perform	$22→$26
Feb 25, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$57→$65
Feb 20, 2026	Canaccord Genuity	Whitney Ijem	Initiate	Buy	$74
Jan 21, 2026	Bernstein	William Pickering	PT Raise	Outperform	$37→$41
Jan 7, 2026	UBS	Michael Yee	Initiate	Neutral	$28
Nov 24, 2025	Evercore ISI Group	Cory Kasimov	Initiate	Outperform	$35
Oct 10, 2025	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$80
Oct 9, 2025	JP Morgan	Eric Joseph	PT Cut	Overweight	$48→$46
Sep 15, 2025	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$80
Aug 6, 2025	Barclays	Gena Wang	PT Cut	Equal-Weight	$25→$21
May 7, 2025	Guggenheim	Debjit Chattopadhyay	PT Cut	Buy	$78→$55
May 7, 2025	Wells Fargo	Yanan Zhu	PT Cut	Overweight	$75→$70

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $80 price target.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target

Wedbush analyst David Nierengarten reiterates Beam Therapeutics (NASDAQ:BEAM) with a Outperform and maintains $65 price target.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target

Wedbush analyst David Nierengarten reiterates Beam Therapeutics (NASDAQ:BEAM) with a Outperform and maintains $65 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $80 price target.

Benzinga Newsdesk

PRO
B of A Securities Reiterates Buy on Beam Therapeutics, Maintains $47 Price Target

B of A Securities analyst Alec Stranahan reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $47 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $80 price target.

Benzinga Newsdesk

Beam Therapeutics Inc

Beam Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

PRO
Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target

PRO
Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

PRO
B of A Securities Reiterates Buy on Beam Therapeutics, Maintains $47 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Beam Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

PRO
Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target

PRO
Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

PRO
B of A Securities Reiterates Buy on Beam Therapeutics, Maintains $47 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

People Also Watch

People Also Watch

Beam Therapeutics Inc

Beam Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

PROWedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target

PROWedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target

PROHC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

PROB of A Securities Reiterates Buy on Beam Therapeutics, Maintains $47 Price Target

PROHC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Beam Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

PROWedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target

PROWedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target

PROHC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

PROB of A Securities Reiterates Buy on Beam Therapeutics, Maintains $47 Price Target

PROHC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

PRO
Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target

PRO
Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

PRO
B of A Securities Reiterates Buy on Beam Therapeutics, Maintains $47 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

PRO
Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target

PRO
Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

PRO
B of A Securities Reiterates Buy on Beam Therapeutics, Maintains $47 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target